Silence Therapeutics PLC (SLN) is a leading biotechnology firm specializing in the discovery, development, and delivery of novel RNA interference (RNAi) therapeutics for the treatment of diseases with significant unmet medical needs. The company’s principal strategic focus is the development of a new class of therapeutics, known as RNAi or 'gene silencing,' aimed at inhibiting the expression of certain disease-causing genes to halt the progression of disease.
Established in 1994 and based in London, the company (under LSE: SLN) has positioned itself on the cutting edge of gene therapy. Silence Therapeutics caters to a wide range of diseases, including cancer, iron overload disorders, cardiovascular diseases, and other rare genetic diseases. The company boasts a proprietary technology platform that provides the ability to develop therapeutic molecules with innovative, targeted, and tolerable delivery mechanisms.
Among the key assets in its broad and diverse pipeline is SLN360, a product candidate that targets lipoprotein(a) to reduce the risk of cardiovascular disease, SLN124, designed to treat patients with iron overload disorders, and SLN500, developed to treat hematological cancer in collaboration with Mallinckrodt.
Given the high scientific and commercial potential of RNAi therapeutics, Silence Therapeutics has been successful in forging long-term strategic alliances with some of the biggest names in the pharmaceutical industry, which help in accelerating its drug development processes. It has inked a partnership with Mallinckrodt Pharmaceuticals, and it also collaborates with Takeda, a global biopharmaceutical company, which primarily caters to oncology and rare disease sectors.
Silence Therapeutics is heavily focused on research and development, striving to push the boundaries in RNA technology to unleash the full potential of its therapeutics. With a robust team of highly skilled professionals, the company continues to chart new territories in its pursuit to develop RNA therapies that could potentially transform patient lives.
Despite the often high-risk nature of the biotech industry, Silence Therapeutics PLC has proven itself to be a stable and robust company through its extensive years of experience in RNAi therapeutics and its consistent dedication to innovation and scientific discovery. The firm is wholly committed to its mission to silence disease through precision-engineered medicines and to bring meaningful benefits to patients.